Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

Yadav, Punit; Cockwell, Paul; Cook, Mark; Pinney, Jennifer; Giles, Hannah; Aung, Yu Sandar; Cairns, David; Owen, Roger G; Davies, Faith E; Jackson, Graham H; Child, J Anthony; Morgan, Gareth J; Drayson, Mark T
BACKGROUND:Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival. This study reports the associations between renal function and disease characteristics including serum free light chain (FLC) level at diagnosis in patients with MM. METHODS:Using data from the Medical Research Council Myeloma IX trial, a multicentre, randomized, open-label, phase III and factorial-design trial, we assessed the relationships between renal function, demographic, and disease characteristics, including serum FLC levels, in 1595 newly diagnosed MM patients. Multivariable linear regression was utilised to identify factors that were associated with renal function at diagnosis. A receiver operating characteristic curve (ROC) was used to identify the optimal threshold for serum FLC level at diagnosis to predict severe RI. RESULTS:(severe RI). In a multivariable analysis, factors independently and negatively associated with eGFR at diagnosis were: higher serum FLC level, female gender, and older age. Elevated serum FLC level at diagnosis, irrespective of the paraprotein type, was strongly associated with severe RI. Receiver operating characteristic curve analysis showed a serum FLC level of > 800 mg/L as the optimal cut-off associated with severe RI (area under curve 0.86, 95% confidence interval 0.77-0.84). CONCLUSION/CONCLUSIONS:There was a strong relationship between higher serum FLC levels at diagnosis and the severity of RI that was irrespective of the paraprotein type. We report an increased risk of severe RI in patients presenting with serum FLC levels above 800 mg/L at diagnosis.
PMCID:6048743
PMID: 30012107
ISSN: 1471-2369
CID: 3649332

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

Gay, Francesca; Jackson, Graham; Rosiñol, Laura; Holstein, Sarah A; Moreau, Philippe; Spada, Stefano; Davies, Faith; Lahuerta, Juan José; Leleu, Xavier; Bringhen, Sara; Evangelista, Andrea; Hulin, Cyrille; Panzani, Ugo; Cairns, David A; Di Raimondo, Francesco; Macro, Margaret; Liberati, Anna Marina; Pawlyn, Charlotte; Offidani, Massimo; Spencer, Andrew; Hájek, Roman; Terpos, Evangelos; Morgan, Gareth J; Bladé, Joan; Sonneveld, Pieter; San-Miguel, Jesús; McCarthy, Philip L; Ludwig, Heinz; Boccadoro, Mario; Mateos, Maria-Victoria; Attal, Michel
Importance/UNASSIGNED:Several trials demonstrated the impact of novel agent-based maintenance in newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating the superiority of one regimen over the other, owing to the lack of direct/indirect comparisons. Objective/UNASSIGNED:To analyze and compare the effectiveness of different maintenance regimens in NDMM via a network meta-analysis. Data Sources/UNASSIGNED:We performed 2 independent searches in PubMed and Cochrane databases, and then we identified all the records registered after 1999 and on or before November 20, 2017. Study Selection/UNASSIGNED:By blinded review, we identified prospective phase 3 randomized trials evaluating novel agent-based maintenance in patients with NDMM; the included studies compared at least 2 maintenance approaches; comparators included placebo and no maintenance. From 364 screened records, 11 studies were included. Data Extraction and Synthesis/UNASSIGNED:We followed (independent extraction) the guidelines provided by the PRISMA Report and the EQUATOR Network. The evidence was synthesized using a network meta-analysis (NMA). To allow comparison of all treatments, no maintenance was selected as common comparator and the effect of placebo was assumed to be the same as no treatment. The best option was identified by a Bayesian consistency model based on hazard ratio (HR), 95% credible interval (CrI), probability of being the best treatment (PbBT), and median ranking distribution (MedR). Main Outcomes and Measures/UNASSIGNED:Outcomes of interest were progression-free survival (PFS) and overall survival (OS). Results/UNASSIGNED:Eleven trials and 8 treatments including a total of 5073 participants were included. By PFS analysis, lenalidomide-based regimens (lenalidomide-prednisone, lenalidomide alone) were identified as the most effective options (HR, 0.39 [95% CrI, 0.28-0.53] and 0.47 [95% CrI, 0.39-0.55], respectively; MedR, 1 and 2; overall PbBT, 74%). Four treatments (thalidomide-interferon, thalidomide-bortezomib, bortezomib-prednisone, thalidomide alone) showed an HR in favor of maintenance. By OS analysis, lenalidomide alone was identified as the best option (HR, 0.76; 95% CrI, 0.51-1.16; MedR, 2; PbBT, 38%), followed by bortezomib-thalidomide and bortezomib-prednisone. Similar features were noticed in the restricted network including transplant trials, in the sensitivity analysis, and in most of the prognostic subgroups. Conclusions and Relevance/UNASSIGNED:Based on PFS and OS results of this NMA, lenalidomide maintenance appears to be the best treatment option, by synthesizing the available evidence of novel agent-based maintenance in the past 20 years.
PMCID:6233774
PMID: 30098165
ISSN: 2374-2445
CID: 3649352

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

Bødker, Julie Støve; Brøndum, Rasmus Froberg; Schmitz, Alexander; Schönherz, Anna Amanda; Jespersen, Ditte Starberg; Sønderkær, Mads; Vesteghem, Charles; Due, Hanne; Nørgaard, Caroline Holm; Perez-Andres, Martin; Samur, Mehmet Kemal; Davies, Faith; Walker, Brian; Pawlyn, Charlotte; Kaiser, Martin; Johnson, David; Bertsch, Uta; Broyl, Annemiek; van Duin, Mark; Shah, Rajen; Johansen, Preben; Nørgaard, Martin Agge; Samworth, Richard J; Sonneveld, Pieter; Goldschmidt, Hartmut; Morgan, Gareth J; Orfao, Alberto; Munshi, Nikhil; Johnson, Hans Erik; El-Galaly, Tarec; Dybkær, Karen; Bøgsted, Martin
Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and optimize therapy. Here we propose a new subtyping of myeloma plasma cells (PCs) from diagnostic samples, assigned by normal B-cell subset associated gene signatures (BAGS). For this purpose, we combined fluorescence-activated cell sorting and gene expression profiles from normal bone marrow (BM) Pre-BI, Pre-BII, immature, naïve, memory, and PC subsets to generate BAGS for assignment of normal BM subtypes in diagnostic samples. The impact of the subtypes was analyzed in 8 available data sets from 1772 patients' myeloma PC samples. The resulting tumor assignments in available clinical data sets exhibited similar BAGS subtype frequencies in 4 cohorts from de novo MM patients across 1296 individual cases. The BAGS subtypes were significantly associated with progression-free and overall survival in a meta-analysis of 916 patients from 3 prospective clinical trials. The major impact was observed within the Pre-BII and memory subtypes, which had a significantly inferior prognosis compared with other subtypes. A multiple Cox proportional hazard analysis documented that BAGS subtypes added significant, independent prognostic information to the translocations and cyclin D classification. BAGS subtype analysis of patient cases identified transcriptional differences, including a number of differentially spliced genes. We identified subtype differences in myeloma at diagnosis, with prognostic impact and predictive potential, supporting an acquired B-cell trait and phenotypic plasticity as a pathogenetic hallmark of MM.
PMCID:6156884
PMID: 30254104
ISSN: 2473-9537
CID: 3649372

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Shah, Vallari; Johnson, David C; Sherborne, Amy L; Ellis, Sidra; Aldridge, Frances M; Howard-Reeves, Julie; Begum, Farzana; Price, Amy; Kendall, Jack; Chiecchio, Laura; Savola, Suvi; Jenner, Matthew W; Drayson, Mark T; Owen, Roger G; Gregory, Walter M; Morgan, Gareth J; Davies, Faith E; Houlston, Richard S; Cook, Gordon; Cairns, David A; Jackson, Graham; Kaiser, Martin F
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 newly diagnosed Myeloma XI trial patients with multiplex ligation-dependent probe amplification (MLPA). Subclonal TP53 deletions were independently associated with shorter overall survival, with a hazard ratio of 1.8 (95% confidence interval, 1.2-2.8; P = .01). Clonal, but not subclonal, TP53 deletions were associated with clinical markers of advanced disease, specifically lower platelet counts (P < .001) and increased lactate dehydrogenase (P < .001), as well as a higher frequency of features indicative of genomic instability, del(13q) (P = .002) or del(1p) (P = .006). Biallelic TP53 loss-of-function by mutation and deletion was rare (2.4%) and associated with advanced disease. We present a framework for identifying subclonal TP53 deletions by MLPA, to improve patient stratification in MM and tailor therapy, enabling management strategies.
PMID: 30373884
ISSN: 1528-0020
CID: 3649382

The genomic landscape of plasma cells in systemic light chain amyloidosis [Letter]

Boyle, Eileen M; Ashby, Cody; Wardell, Christopher P; Rowczenio, Dorota; Sachchithanantham, Sajitha; Wang, Yan; Johnson, Sarah K; Bauer, Michael A; Weinhold, Niels; Kaiser, Martin F; Johnson, David C; Jones, John R; Pawlyn, Charlotte; Proszek, Paula; Schinke, Carolina; Facon, Thierry; Dumontet, Charles; Davies, Faith E; Morgan, Gareth J; Walker, Brian A; Wechalekar, Ashutosh D
PMID: 30446495
ISSN: 1528-0020
CID: 3649392

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses [Letter]

Yao, Qiumei; Morgan, Gareth J; Chim, Chor Sang
Spatial and subclonal genetic heterogeneity in multiple myeloma (MM) have been demonstrated by sequencing of plasma cells from multi-focal regions, but studies of spatial epigenetic heterogeneity are scanty. Herein, promoter methylation status of genes implicated in disease progression (CDKN2A and SHP1) and marrow escape (CDH1, CD56, and CXCR4) was studied in two patients with multi-focal extramedullary relapses. Patient 1 developed simultaneous chest wall and duodenal plasmacytoma at relapse. While SHP1 and CDKN2A were hypermethylated in both plasmacytomas, CDH1 hypermethylation was detected only in the chest wall. In patient 2, SHP1 methylation was found in the extradural plasmacytoma but not bone marrow (BM) at diagnosis, and the circulating PCs but not the BM at relapse. As the clonality, based on sequence of the complementarity-determining region 3 (CDR3) of the immunoglobulin gene, was conserved in plasma cells at diagnosis and relapse, differential methylation of CDH1 in patient 1 and SHP1 in patient 2 was an illustration of spatial epigenetic heterogeneity. Furthermore, subclonal epigenetic heterogeneity was identified by the presence of subclonal SHP1 promoter methylation within the chest wall plasmacytoma of patient 1. In summary, our data showed distinct promoter methylation profile of plasma cells from multiple regions. This is the first report of spatial epigenetic heterogeneity in MM.
PMCID:6302381
PMID: 30572945
ISSN: 1868-7083
CID: 3649412

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

Went, Molly; Sud, Amit; Speedy, Helen; Sunter, Nicola J; Försti, Asta; Law, Philip J; Johnson, David C; Mirabella, Fabio; Holroyd, Amy; Li, Ni; Orlando, Giulia; Weinhold, Niels; van Duin, Mark; Chen, Bowang; Mitchell, Jonathan S; Mansouri, Larry; Juliusson, Gunnar; Smedby, Karin E; Jayne, Sandrine; Majid, Aneela; Dearden, Claire; Allsup, David J; Bailey, James R; Pratt, Guy; Pepper, Chris; Fegan, Chris; Rosenquist, Richard; Kuiper, Rowan; Stephens, Owen W; Bertsch, Uta; Broderick, Peter; Einsele, Hermann; Gregory, Walter M; Hillengass, Jens; Hoffmann, Per; Jackson, Graham H; Jöckel, Karl-Heinz; Nickel, Jolanta; Nöthen, Markus M; da Silva Filho, Miguel Inacio; Thomsen, Hauke; Walker, Brian A; Broyl, Annemiek; Davies, Faith E; Hansson, Markus; Goldschmidt, Hartmut; Dyer, Martin J S; Kaiser, Martin; Sonneveld, Pieter; Morgan, Gareth J; Hemminki, Kari; Nilsson, Björn; Catovsky, Daniel; Allan, James M; Houlston, Richard S
The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (Rg = 0.4, P = 0.0046). Furthermore, four of the 45 known CLL risk loci were shown to associate with MM risk and five of the 23 known MM risk loci associate with CLL risk. By integrating eQTL, Hi-C and ChIP-seq data, we show that these pleiotropic risk loci are enriched for B-cell regulatory elements and implicate B-cell developmental genes. These data identify shared biological pathways influencing the development of CLL and, MM and further our understanding of the aetiological basis of these B-cell malignancies.
PMCID:6315026
PMID: 30602759
ISSN: 2044-5385
CID: 3649432

The genomic features associated with high-risk multiple myeloma [Comment]

Walker, Brian A; Morgan, Gareth J
PMID: 30464803
ISSN: 1949-2553
CID: 3649712

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Went, Molly; Sud, Amit; Försti, Asta; Halvarsson, Britt-Marie; Weinhold, Niels; Kimber, Scott; van Duin, Mark; Thorleifsson, Gudmar; Holroyd, Amy; Johnson, David C; Li, Ni; Orlando, Giulia; Law, Philip J; Ali, Mina; Chen, Bowang; Mitchell, Jonathan S; Gudbjartsson, Daniel F; Kuiper, Rowan; Stephens, Owen W; Bertsch, Uta; Broderick, Peter; Campo, Chiara; Bandapalli, Obul R; Einsele, Hermann; Gregory, Walter A; Gullberg, Urban; Hillengass, Jens; Hoffmann, Per; Jackson, Graham H; Jöckel, Karl-Heinz; Johnsson, Ellinor; Kristinsson, Sigurður Y; Mellqvist, Ulf-Henrik; Nahi, Hareth; Easton, Douglas; Pharoah, Paul; Dunning, Alison; Peto, Julian; Canzian, Federico; Swerdlow, Anthony; Eeles, Rosalind A; Kote-Jarai, ZSofia; Muir, Kenneth; Pashayan, Nora; Nickel, Jolanta; Nöthen, Markus M; Rafnar, Thorunn; Ross, Fiona M; da Silva Filho, Miguel Inacio; Thomsen, Hauke; Turesson, Ingemar; Vangsted, Annette; Andersen, Niels Frost; Waage, Anders; Walker, Brian A; Wihlborg, Anna-Karin; Broyl, Annemiek; Davies, Faith E; Thorsteinsdottir, Unnur; Langer, Christian; Hansson, Markus; Goldschmidt, Hartmut; Kaiser, Martin; Sonneveld, Pieter; Stefansson, Kari; Morgan, Gareth J; Hemminki, Kari; Nilsson, Björn; Houlston, Richard S
Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM.
PMID: 30213928
ISSN: 2041-1723
CID: 3649662

Cure-Rate Survival Models and Their Application to Cancer Clinical Trials

Chapter by: Othus, Megan; Mitchell, Alan; Barlogie, Bart; Morgan, Gareth; Crowley, John
in: Frontiers of biostatistical methods and applications in clinical oncology by Matsui, Shigeyuki; Crowley, John (Eds)
Singapore : Springer, [2017]
pp. 165-178
ISBN: 9789811001260
CID: 3708772